Cleary, Darryl G.,Reynolds, Charles J.,Berrey, Miriam Michelle,Hindes, Robert G.,Symonds, William T.,Ray, Adrian S.,Mo, Hongmei,Hebner, Christy M.,Oliyai, Reza,Zia, Vahid,Stefanidis, Dimitrios,Pakdama
申请号：
AU2012346217
公开号：
AU2012346217A1
申请日:
2012.11.27
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
